Radiogenomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers

This study is currently recruiting participants.
Verified October 2013 by Samsung Medical Center
Sponsor:
Information provided by (Responsible Party):
Ho Yun Lee, Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT01585545
First received: April 21, 2012
Last updated: October 18, 2013
Last verified: October 2013

April 21, 2012
October 18, 2013
October 2013
October 2015   (final data collection date for primary outcome measure)
functional and genetic profile of lung cancer [ Time Frame: two years ] [ Designated as safety issue: No ]

following parameters will be calculated using these values:

  1. Metabolic parameters on FDG-PET
  2. Perfusion parameters on DCE-MRI
  3. Diffusion parameters on DWI
  4. Mutation analysis of lung cancer tissue
Same as current
Complete list of historical versions of study NCT01585545 on ClinicalTrials.gov Archive Site
relationship between genetic and multiparametric imaging profiling [ Time Frame: two years ] [ Designated as safety issue: No ]
We will evaluate if certain relationship exists between changes in multiparametric imaging markers(metabolic parameters on FDG-PET, perfusion parameters on DCE-MRI, diffusion parameters on DWI) and genetic mutation pattern of NSCLC.
Same as current
Not Provided
Not Provided
 
Radiogenomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
Radiogenomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers

The purpose of this study is to evaluate relationships between multiparametric imaging biomarkers and genetic analysis in NSCLC patients.

To evaluate relationships between multiparametric imaging biomarkers(MRI, PET/CT) and genetic analysis in NSCLC patients

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

lung cance tissue

Non-Probability Sample

The patients with non-small cell lung cancer

Lung Cancer
Not Provided
patients with NSCLC
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
October 2015
October 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Suspected lung cancer on chest chest CT or histologically proven NSCLC
  • Participant is being considered for the conventional/neoadjuvant/targeted chemotherapy or surgery
  • At least one measurable primary or other intrathoracic lesion >= 2cm, according to RECIST
  • Performance status of 0 to 2 on the ECOG scale
  • Age 20 years or older
  • Able to tolerable PET/CT and MRI imaging required by protocol
  • Able to undergo percutaneous needle biopsy before and after chemotherapy
  • Able to give study-specific informed consent

Exclusion Criteria:

  • Poorly controlled diabetes
  • Contraindication for MRI contrast agent
Both
20 Years and older
No
Contact: Ho Yun Lee, Dr 82-2-3410-2502 ext 82-2-3410-2502 hoyunlee96@gmail.com
Korea, Republic of
 
NCT01585545
2012-03-068
Yes
Ho Yun Lee, Samsung Medical Center
Samsung Medical Center
Not Provided
Principal Investigator: Ho Yun Lee, Dr Samsung Medical Center
Samsung Medical Center
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP